
| Cat. No. |
Size |
Price |
Figures |
RP10804-0.5 mg
| 0.5 mg | $ 71.25 | MSDS: 20080630212733 (PDF)
References:
- Korolkiewicz RP, et al. Mechanism of the contractile effects of galantide and Galanin(1-14) [alpha-aminobutyric acid]scyliorhinin-I in rat isolated fundus strips. Med. Sci. Monit. Jan 2002; 8(1): BR19-BR23.
- Bivalacqua TJ, et al. Nitric oxide-mediated erectile effects of galantide but not galanin in vivo. Nitric. Oxide. Apr 2000; 4(2): 94-102.
|
|---|
| Full Name | |
Sequence (one-letter code) |
GWTLNSAGYLLGPQQFFGLM-NH2 | Sequence (three-letter code) | {GLY}{TRP}{THR}{LEU}{ASN}{SER}{ALA}{GLY}{TYR}{LEU} {LEU}{GLY}{PRO}{GLN}{GLN}{PHE}{PHE}{GLY}{LEU}{MET} | | C-Terminal | NH2 |
|---|
| Description | The galanin-antagonist galantide, a chimeric peptide obtained from amino acids 1-13 of galanin attached to the C-terminal fragment of bradykinin, has been found to improve social memory in 'social recognition' test when i.c.v. administered at doses varying from 6-6000nmoles. Galantide causes widespread antagonism to the action of galanin and reversibly blocks the neuronal actions of galanin in a dose-dependent manner. It inhibits the release of acetylcholine, reduces the response to galanin in the hypothalamus, and blocks the effect of galanin on glucose-induced insulin secretion. |
|---|
| Solubility | Soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents. |
|---|
| Formula | C104H151N25O26S1 | | M.W. | 2199.6 | | Cas | 138579-66-5 |
|---|
| Purity | > 95% | | Storage | store at -20°C. Keep tightly closed. Store in a cool dry place. |
| * For Non-Clinical Research Use Only *If you cannot find your peptides on our list, try our Express PeptideTM Service, and receive high-quality peptides in eight business days, guaranteed. Our customer service is available 24 hours a day, Monday through Friday. You may contact us any time for assistance.
|
|